AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study - Nasdaq

AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study  Nasdaq

AstraZeneca Plc AZN announced positive overall survival (OS) results from the phase III CASPIAN study evaluating Imfinzi (durvalumab) in first-line ...



Comments

Popular posts from this blog

Oncology: The disease, dynamics & challenges of market research

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Lung Cancer Among People Who Never Smoked